The Role of Gamma Delta T Lymphocytes in Physiological and Pathological Condition—Focus on Psoriasis, Atopic Dermatitis, Autoimmune Disorders, Cancer and Lymphomas DOI Open Access
Joanna Chojnacka‐Purpurowicz, Agnieszka Owczarczyk‐Saczonek, Bogusław Nedoszytko

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(14), P. 7960 - 7960

Published: July 21, 2024

Gamma delta (γδ) T cells are a heterogeneous population of that play roles in inflammation, host tissue repair, clearance viral and bacterial pathogens, regulation immune processes, tumor surveillance. Recent research suggests these the main skin produce interleukin-17 (I-17). Furthermore, γδ exhibit memory-cell-like characteristics mediate repeated episodes psoriatic inflammation. found epithelial tissues, where many cancers develop. There, they participate antitumor immunity as cytotoxic or coordinators. also defense, surveillance, homeostasis. The aim this review is to present importance physiological pathological diseases, such psoriasis, atopic dermatitis, autoimmune cancer, lymphoma.

Language: Английский

The emerging roles of γδ T cells in cancer immunotherapy DOI
Sofia Mensurado, Rafael Blanco-Domínguez, Bruno Silva‐Santos

et al.

Nature Reviews Clinical Oncology, Journal Year: 2023, Volume and Issue: 20(3), P. 178 - 191

Published: Jan. 9, 2023

Language: Английский

Citations

202
The present and future of bispecific antibodies for cancer therapy DOI
Christian Klein, Ulrich Brinkmann, Janice M. Reichert

et al.

Nature Reviews Drug Discovery, Journal Year: 2024, Volume and Issue: 23(4), P. 301 - 319

Published: March 6, 2024

Language: Английский

Citations

135
γδ T cells: origin and fate, subsets, diseases and immunotherapy DOI Creative Commons
Yi Hu,

Qinglin Hu,

Yongsheng Li

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2023, Volume and Issue: 8(1)

Published: Nov. 22, 2023

The intricacy of diseases, shaped by intrinsic processes like immune system exhaustion and hyperactivation, highlights the potential renormalization as a promising strategy in disease treatment. In recent years, our primary focus has centered on γδ T cell-based immunotherapy, particularly pioneering use allogeneic Vδ2

Language: Английский

Citations

113
Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment DOI Creative Commons
Zhifei Gao, Yifeng Bai, Anqi Lin

et al.

Molecular Cancer, Journal Year: 2023, Volume and Issue: 22(1)

Published: Feb. 15, 2023

Abstract As a nontraditional T-cell subgroup, γδT cells have gained popularity in the field of immunotherapy recent years. They extraordinary antitumor potential and prospects for clinical application. Immune checkpoint inhibitors (ICIs), which are efficacious tumor patients, become pioneer drugs since they were incorporated into practice. In addition, that infiltrated tissues found to be state exhaustion or anergy, there is upregulation many immune checkpoints (ICs) on their surface, suggesting similar ability respond ICIs as traditional effector T cells. Studies shown targeting ICs can reverse dysfunctional microenvironment (TME) exert effects by improving γδT-cell proliferation activation enhancing cytotoxicity. Clarification functional TME mechanisms underlying interaction with will solidify combined good treatment option.

Language: Английский

Citations

73
New immune cell engagers for cancer immunotherapy DOI

Aurore Fenis,

Olivier Demaria, Laurent Gauthier

et al.

Nature reviews. Immunology, Journal Year: 2024, Volume and Issue: 24(7), P. 471 - 486

Published: Jan. 25, 2024

Language: Английский

Citations

67
Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met? DOI Creative Commons
Caroline Lonez, Eytan Breman

Cells, Journal Year: 2024, Volume and Issue: 13(2), P. 146 - 146

Published: Jan. 12, 2024

This last decade, chimeric antigen receptor (CAR) T-cell therapy has become a real treatment option for patients with B-cell malignancies, while multiple efforts are being made to extend this other malignancies and broader patient populations. However, several limitations remain, including those associated the time-consuming highly personalized manufacturing of autologous CAR-Ts. Technologies establish "off-the-shelf" allogeneic CAR-Ts low alloreactivity currently developed, strong focus on gene-editing technologies. Although these technologies have many advantages, they also limitations, double-strand breaks in DNA safety risks as well lack modulation. As an alternative, non-gene-editing provide interesting approach support development future, possibilities fine-tuning gene expression easy development. Here, we will review different ways can be manufactured discuss which used. The biggest hurdles successful summarized, finally, overview current clinical evidence comparison its counterpart given.

Language: Английский

Citations

21
The interaction of innate immune and adaptive immune system DOI Creative Commons

Ruyuan Wang,

Caini Lan, Kamel Benlagha

et al.

MedComm, Journal Year: 2024, Volume and Issue: 5(10)

Published: Sept. 15, 2024

The innate immune system serves as the body's first line of defense, utilizing pattern recognition receptors like Toll-like to detect pathogens and initiate rapid response mechanisms. Following this initial response, adaptive immunity provides highly specific sustained killing via B cells, T antibodies. Traditionally, it has been assumed that activates immunity; however, recent studies have revealed more complex interactions. This review a detailed dissection composition function systems, emphasizing their synergistic roles in physiological pathological contexts, providing new insights into link between these two forms immunity. Precise regulation both systems at same time is beneficial fight against immune-related diseases, for example, cGAS-STING pathway found play an important role infections cancers. In addition, paper summarizes challenges future directions field immunity, including latest single-cell sequencing technologies, CAR-T cell therapy, checkpoint inhibitors. By summarizing developments, aims enhance our understanding complexity interactions perspectives system.

Language: Английский

Citations

18
A close look at current γδ T-cell immunotherapy DOI Creative Commons
Ling Ma,

Yanmin Feng,

Zishan Zhou

et al.

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: March 31, 2023

Owing to their antitumor and major histocompatibility complex (MHC)-independent capacities, γδ T cells have gained popularity in adoptive T-cell immunotherapy recent years. However, many unknowns still exist regarding cells, few clinical data been collected. Therefore, this review aims describe all the main features of applications provide a systematic view current immunotherapy. Specifically, will focus on how performed treating cancers clinics, trials that conducted date, role pharmaceutical industry.

Language: Английский

Citations

30
Advancements in γδT cell engineering: paving the way for enhanced cancer immunotherapy DOI Creative Commons

Megan Yuan,

Wenjun Wang,

Isobel Hawes

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: March 21, 2024

Comprising only 1-10% of the circulating T cell population, γδT cells play a pivotal role in cancer immunotherapy due to their unique amalgamation innate and adaptive immune features. These can secrete cytokines, including interferon-γ (IFN-γ) tumor necrosis factor-α (TNF-α), directly eliminate through mechanisms like Fas/FasL antibody-dependent cell-mediated cytotoxicity (ADCC). Unlike conventional αβT cells, target wide variety independently major histocompatibility complex (MHC) presentation function as antigen-presenting (APCs). Their ability recognizing antigens non-MHC restricted manner makes them an ideal candidate for allogeneic immunotherapy. Additionally, exhibit specific tissue tropism, rapid responsiveness upon reaching cellular targets, indicating high level precision adaptability. Despite these capabilities, therapeutic potential has been hindered by some limitations, abundance, unsatisfactory expansion, limited persistence, biology plasticity. To address issues, gene-engineering strategies use chimeric antigen receptor (CAR) therapy, (TCR) gene transfer, combination with engagers are being explored. This review will outline progress various engineering strategies, discuss implications challenges that lie ahead, future directions engineered both monotherapy

Language: Английский

Citations

10
Photosensitive Hybrid γδ-T Exosomes for Targeted Cancer Photoimmunotherapy DOI Creative Commons
Yifan Gao, Jinzhao Liu,

Meicen Wu

et al.

ACS Nano, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 25, 2025

Melanoma is the most aggressive type of skin cancers. Traditional chemotherapy and radiotherapy have limited effectiveness can lead to systemic side effects. Photodynamic therapy (PDT) a photoresponsive cancer based on photosensitizers generate reactive oxygen species (ROS) eradicate tumor cells. Our previous study showed that exosomes derived from human γδ-T cells (γδ-T exosomes) could control Epstein–Barr virus-associated tumors. Here, we combined PDT for targeted photoimmunotherapy by membrane fusion Chlorin e6 (Ce6)-loaded liposomes. The functional surface proteins, such as CCR5 PD-1, hybrid mediated specific binding toward melanoma tissues. cytolytic molecules, granzyme A, B, perforin, granulysin exosomes, induced apoptosis without harming normal In response light irradiation, ROS generation inside synergized with molecules induce promote immunogenic cell death (ICD). subsequently released damage-associated molecular patterns (DAMPs) stimulate dendritic maturation antigen-specific CD4+ CD8+ T-cell responses, thereby enhancing antitumor immunity. This provides promising strategy combining photoimmunotherapy, expanding clinical applications exosome patients.

Language: Английский

Citations

1